LLY

910.17

+0.51%↑

UNH

569.99

-0.12%↓

NVO

116.46

-0.73%↓

JNJ

163.54

+0.57%↑

ABBV

188.97

+1.46%↑

LLY

910.17

+0.51%↑

UNH

569.99

-0.12%↓

NVO

116.46

-0.73%↓

JNJ

163.54

+0.57%↑

ABBV

188.97

+1.46%↑

LLY

910.17

+0.51%↑

UNH

569.99

-0.12%↓

NVO

116.46

-0.73%↓

JNJ

163.54

+0.57%↑

ABBV

188.97

+1.46%↑

LLY

910.17

+0.51%↑

UNH

569.99

-0.12%↓

NVO

116.46

-0.73%↓

JNJ

163.54

+0.57%↑

ABBV

188.97

+1.46%↑

LLY

910.17

+0.51%↑

UNH

569.99

-0.12%↓

NVO

116.46

-0.73%↓

JNJ

163.54

+0.57%↑

ABBV

188.97

+1.46%↑

Accueil・Liste d'Actions・Bio-Techne Corp

Bio-Techne Corp

Fermé

Secteur Soins de santé

69.94 -0.48

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

68.71

Max

70.47

Chiffres clés
By Trading Economics
Revenu	-8.5M 41M
Ventes	-303B 306M
P/E Moyenne du Secteur	50.64 112.16
BPA	0.49
Marge bénéficiaire	13.26
EBITDA	92M

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+14.11 upside

Dividendes
By Dow Jones
Prochains Résultats	30 oct. 2024
Date du Prochain Dividende	22 nov. 2024
Date du Prochain Détachement de Dividende	7 nov. 2024

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-972M 11B
Ouverture précédente	70.42
Clôture précédente	69.94

Sentiment de l'Actualité

By Acuity

77%

23%

351 / 366 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bearish Evidence

69.93 / 73.74 Support & Résistance

Bio-Techne Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

21 oct. 2024, 23:17 UTC

Actualités

Australian Consumer Confidence Highest Since Early 2023

21 oct. 2024, 20:42 UTC

Résultats

SAP 3Q Revenue, Profit Climb on AI Demand; Outlook Raised

21 oct. 2024, 22:57 UTC

Résultats

Ping An Insurance: Higher Income From Healthcare, Senior-Care Services Supported Results >2318.HK

21 oct. 2024, 22:57 UTC

Résultats

Ping An Insurance 9-Mos Rev CNY861.8B ; Up 8.7% on Year >2318.HK

21 oct. 2024, 22:57 UTC

Résultats

Ping An Insurance 9-Mos Net CNY119.2B; Up 36.1% on Year >2318.HK

21 oct. 2024, 22:10 UTC

Market Talk

Acquisitions, Fusions, Rachats

Webjet Looks Like an M&A Target, But Bids Unlikely Soon -- Market Talk

21 oct. 2024, 21:02 UTC

Acquisitions, Fusions, Rachats

Sanofi Deal Jitters Imperil Stock's Big Rebound -- Barrons.com

21 oct. 2024, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

21 oct. 2024, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

21 oct. 2024, 20:50 UTC

Market Talk

Résultats

Tech, Media & Telecom Roundup: Market Talk

21 oct. 2024, 20:32 UTC

Résultats

Nucor: The Earnings of the Raw Materials Segment Are Expected to Increase in 4Q Compared to 3Q >NUE

21 oct. 2024, 20:31 UTC

Résultats

Nucor: Expect Consolidated Net Earnings Attributable to Nucor Stockholders in 4Q to Decrease >NUE

21 oct. 2024, 20:30 UTC

Résultats

Nucor 3Q Total Tons Shipped to Outside Customers Down 1% >NUE

21 oct. 2024, 20:30 UTC

Résultats

Nucor 3Q Steel Mills Total Shipments 5.72M Tons >NUE

21 oct. 2024, 20:30 UTC

Résultats

Nucor 3Q Average Sales Price Per Ton Down 15% >NUE

21 oct. 2024, 20:30 UTC

Résultats

Nucor 3Q EPS $1.05 >NUE

21 oct. 2024, 20:30 UTC

Résultats

Nucor 3Q Sales $7.44B >NUE

21 oct. 2024, 20:30 UTC

Résultats

Nucor 3Q Net $249.9M >NUE

21 oct. 2024, 20:20 UTC

Acquisitions, Fusions, Rachats

Glendon Capital Filing Mentions Reuters Article About Glendon Opposition to Verizon Deal

21 oct. 2024, 20:20 UTC

Actualités

Nvidia Reaches $3.5 Trillion Market Value. It's Right on Apple's Heels. -- Barrons.com

21 oct. 2024, 20:19 UTC

Acquisitions, Fusions, Rachats

Frontier Communications Shareholder Glendon Capital Will Continue to Engage in Talks With Relevant Parties About Sale to Verizon

21 oct. 2024, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

21 oct. 2024, 20:14 UTC

Actualités

S&P 500, Dow Slip; Bond Yields Rise -- WSJ

21 oct. 2024, 20:10 UTC

Résultats

SAP Backs 2024 Cloud Revenue EUR17B-EUR17.3B >SAP

21 oct. 2024, 20:10 UTC

Résultats

SAP Raises 2024 Cloud and Software Revenue View to EUR29.5B-EUR29.8B >SAP

21 oct. 2024, 20:08 UTC

Résultats

SAP Sees Exiting 2024 at Headcount Slightly Ahead of Year-End 2023 >SAP

21 oct. 2024, 20:07 UTC

Résultats

SAP 3Q Cloud and Software Revenue EUR7.43B >SAP

21 oct. 2024, 20:07 UTC

Résultats

SAP 3Q Software Licenses Revenue EUR280M>SAP

21 oct. 2024, 20:06 UTC

Résultats

SAP 3Q Adj EPS EUR1.23 >SAP

21 oct. 2024, 20:06 UTC

Résultats

SAP 3Q EPS EUR1.25 >SAP

Comparaison

Variation de prix

Bio-Techne Corp prévision

Objectif de Prix

By TipRanks

14.11% hausse

Prévisions sur 12 Mois

Moyen 81.29 USD 14.11%

Haut 95 USD

Bas 65 USD

Basé sur 7 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

7 ratings

Achat

Maintien

Vente

Basé sur 7 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

69.93 / 73.74Support & Résistance

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

351 / 366Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Bio-Techne Corp

Bio-Techne Corporation is a developer, manufacturer, and seller of life science reagents, instruments and services for the research, diagnostics, and bioprocessing markets. The Company operates through two segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated, that offer researchers and pharmaceutical manufacturers efficient options for automated western blot and multiplexed ELISA workflow. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits.